The search for dependable molecular biomarkers to enhance routine clinical practice is a compelling challenge across all oncology fields. Urothelial bladder carcinoma, known for its significant heterogeneity, presents difficulties in predicting responses to systemic therapies and outcomes post-radical cystectomy. Recent advancements in molecular cancer biology offer promising avenues to understand the disease’s biology and identify emerging predictive biomarkers. Stratifying patients based on their recurrence risk post-curative treatment or predicting the efficacy of conventional and targeted therapies could catalyze personalized treatment selection and disease surveillance. Despite progress, reliable molecular biomarkers to forecast responses to systemic agents, in neoadjuvant, adjuvant, or palliative treatment settings, are still lacking, underscoring an urgent unmet need. This review aims to delve into the utilization of current and emerging molecular signatures across various stages of urothelial bladder carcinoma to predict responses to systemic therapy.
在所有肿瘤学领域中，寻找可靠的分子生物标志物以提升常规临床实践是一项极具挑战性的任务。尿路上皮膀胱癌以其显著的异质性而闻名，这给预测其对系统性治疗的反应以及根治性膀胱切除术后的预后带来了困难。近年来，分子癌症生物学的进展为理解该疾病的生物学特性及识别新兴的预测性生物标志物提供了有希望的途径。根据患者在接受根治性治疗后复发风险进行分层，或预测传统疗法与靶向治疗的疗效，可能推动个体化治疗方案的选择和疾病监测。尽管已取得进展，但在新辅助、辅助或姑息治疗背景下，仍缺乏可靠的分子生物标志物来预测对系统性药物的反应，这突显了当前亟待满足的临床需求。本综述旨在深入探讨当前及新兴的分子标志物在尿路上皮膀胱癌不同阶段中的应用，以预测对系统性治疗的反应。
肿瘤(癌症)患者之家